Not actual patients.
The safety of Joenja is based on data from both the placebo-controlled pivotal trial and the interim results from the OLE study

Adverse reactions reported by 2 Joenja-treated patients and more frequently than placebo

  • No serious adverse drug reactions
    were reported
  • No patients withdrew due to an adverse
    drug reaction
  • The most common adverse reactions (>10%) were headache, sinusitis, and dermatitis atopic

*Dermatitis atopic: including dermatitis atopic and eczema.

Tachycardia: including tachycardia and sinus tachycardia.

ANC, absolute neutrophil count; OLE, open-label extension.

Seven (33%) patients receiving JOENJA developed an ANC between 500 and 1500 cells/microL. No patients developed an ANC <500 cells/microL and there were no reports of infection associated with neutropenia.